You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the COPIKTRA (duvelisib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR COPIKTRA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for COPIKTRA

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03961672 ↗	Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2020-05-13	This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
NCT03961672 ↗	Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Recruiting	City of Hope Medical Center	Phase 2	2020-05-13	This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
NCT03961672 ↗	Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Recruiting	OHSU Knight Cancer Institute	Phase 2	2020-05-13	This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
NCT04193293 ↗	A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer	Suspended	SecuraBio	Phase 1/Phase 2	2020-02-25	This study will assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
NCT04193293 ↗	A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer	Suspended	Verastem, Inc.	Phase 1/Phase 2	2020-02-25	This study will assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
NCT04331119 ↗	Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas	Recruiting	SecuraBio	Phase 2	2020-07-23	The investigators hypothesize that duvelisib maintenance after autologous stem cell transplant with carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning in patients with T-cell lymphomas, or a history of indolent B-cell lymphomas, will be safe and well tolerated, and will improve progression free survival.
NCT04331119 ↗	Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas	Recruiting	Verastem, Inc.	Phase 2	2020-07-23	The investigators hypothesize that duvelisib maintenance after autologous stem cell transplant with carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning in patients with T-cell lymphomas, or a history of indolent B-cell lymphomas, will be safe and well tolerated, and will improve progression free survival.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for COPIKTRA

Condition Name

Chart
Table

Condition Name for COPIKTRA
Intervention	Trials
COVID-19	2
Refractory Follicular Lymphoma	1
Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8	1
Non Hodgkin Lymphoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for COPIKTRA
Intervention	Trials
Lymphoma	6
COVID-19	2
Neoplasms	2
Lymphoma, B-Cell	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for COPIKTRA

Trials by Country

Map
Table

Trials by Country for COPIKTRA
Location	Trials
United States	15
China	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for COPIKTRA
Location	Trials
Missouri	3
Pennsylvania	3
Georgia	2
Massachusetts	2
Florida	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for COPIKTRA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for COPIKTRA
Clinical Trial Phase	Trials
Phase 2	5
Phase 1/Phase 2	3
Phase 1	3
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for COPIKTRA
Clinical Trial Phase	Trials
Recruiting	9
Not yet recruiting	2
Suspended	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for COPIKTRA

Sponsor Name

Chart
Table

Sponsor Name for COPIKTRA
Sponsor	Trials
Verastem, Inc.	5
Secura Bio, Inc.	3
National Cancer Institute (NCI)	3
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for COPIKTRA
Sponsor	Trials
Industry	14
Other	11
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.